The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
LANCELOT-ACS<br />
PDF-XChange Viewer<br />
w w w.docu-track.co m<br />
Click to buy NOW!<br />
Incidence <strong>of</strong> any CURE Bleed<strong>in</strong>g<br />
PDF-XChange Viewer<br />
w w w.docu-track.co m<br />
Click to buy NOW!<br />
7.0%<br />
CURE m<strong>in</strong>or<br />
6.0%<br />
5.0%<br />
4.0%<br />
3.0%<br />
2.0%<br />
1.0%<br />
0.0%<br />
2.2%<br />
2.2%<br />
Placebo<br />
n=138<br />
Relative Risk (95% CI)<br />
vs. placebo<br />
3.1%<br />
1.3%<br />
1.8%<br />
Active <strong>com</strong>b<strong>in</strong>ed<br />
atopaxar<br />
n=455<br />
RR 1.42 (0.44-4.8)<br />
P = 0.63<br />
1.3%<br />
0.7%<br />
0.6%<br />
2.6%<br />
3.2%<br />
CURE major<br />
0.7%<br />
1.4%<br />
50mg QD 100mg QD 200mg QD<br />
RR 0.60 (0.11-3.00)<br />
P = 0.62<br />
5.8%<br />
RR 2.65 (0.78-10.3)<br />
P = 0.13<br />
P trend = 0.81<br />
2.1%<br />
n=153 n=156 n=146<br />
RR 0.95 (0.18-5.04)<br />
P = 0.99
Change language